Turn Therapeutics Inc.
TTRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Turn Therapeutics Inc. (TTRX) is listed under Biotechnology. The $312.2M market capitalization puts TTRX squarely in small-cap range for its industry. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Market Cap
$312.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-68.53
EPS (TTM)
$-0.29
EPS (Fwd)
$-0.15
ROE
-686.3%
ROA
-50.3%
Cash
$10.3M
Total Debt
$6.1M
Free CF
$4.2M
52W Change
106.8%
Annual Financials
Cash vs Debt
Where TTRX stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, TTRX finished 50.14% above its 150-day moving average ($7.40) and 69.62% above its 200-day moving average ($6.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TTRX overbought or oversold?
At the October 13, 2026 close, TTRX's RSI(14) was 29.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $10.3M in cash and $6.1M in debt, TTRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $4.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -686.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Investors considering Turn Therapeutics Inc. should weigh the typical risks associated with TTRX's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Turn Therapeutics Inc. and its sector.